Funder
Spanish Cooperative Group for the Treatment of Digestive Tumours
TTD
Spanish Ministry of Health, Social Services and Equality
Ministerio de Sanidad, Servicios Sociales e Igualdad
Amgen
Bayer
Celgene
Merck
Roche
Sanofi
Reference26 articles.
1. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study;Douillard;JCO,2010
2. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer;Peeters;JCO,2010
3. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials;Liang;Drug Des Dev Ther,2015
4. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;JCO,2008
5. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献